How do you sequence systemic therapies for recurrent/metastatic head/neck cancer following the recent approval of pembrolizumab?
Do HPV and/or PD-L1 status influence your decision making?
Answer from: Medical Oncologist at Academic Institution
We currently do not have any available predictive biomarker to inform us on which patients will respond to PD-1 inhibitors based on recently presented data. This work remains investigational. Hence, we do not check PD-1 status to determine whether or not patients should receive immunotherapy. ...
Sign in or Register to read more